Developing novel biological drugs for complex chronic diseases

Targeting TGF-β for fibrosis and cancer. 

Newly discovered

Novel soluble splice variant of human TGF-β type II receptor fused to antibody Fc domain

Binds TGF-β1, β2, & β3

Unique 13 amino acid stretch allows the binding to the three isoforms of TGF-β, to maximize its potential application on several indications

Decoy receptor

Our biomolecule neutralizes excessive TGF-β levels observed in several conditions

About us

Overview

RADBIO is a biotech company founded in 2018 by experienced scientists and entrepreneurs, designing and developing a novel biomolecule that neutralizes TGF-β, as a therapeutic for fibrotic diseases and solid tumors with unmet medical needs.

Strategy

TGF-β is a well validated target known as the “master regulator of fibrosis”. We aim at harnessing the potential application of our biomolecule in several indications where TGF-β isoforms are upregulated.

INDICATION

DISCOVERY & CHARACTERIZATION

PROOF OF CONCEPT STUDIES

PRECLINICAL CMC / GLP-TOX

CLINICAL PHASES

BRECEPT

Inhibitor of TGF-β signaling pathway